NEW YORK, Feb. 9, 2021 /PRNewswire/ — Synaptogenix, Inc. (OTC: SNPX) (the “Organization”), an rising biopharmaceutical company centered on building therapies for neurodegenerative illnesses, announced that it has submitted a formal application to checklist its frequent shares on the Nasdaq Stock Market place (“Nasdaq”).
The Organization intends to satisfy all of the applicable listing necessities however, there is no assurance that its application will be approved. In the course of the Nasdaq review procedure, the Company’s typical inventory will go on to trade on the OTC beneath its existing symbol, SNPX.
Dr. Alan J. Tuchman, CEO of Synaptogenix, mentioned, “Subsequent our current financing, Synaptogenix is effectively funded to go through our Countrywide Institutes of Wellbeing sponsored, double blinded, Period 2 scientific demo. We are emboldened by recent investor desire in the newer ways to Alzheimer’s which we have been a chief in for a lot more than 30 yrs. We glance forward to updating shareholders on our trial progress, as properly as any ancillary trials which are initiated, in the close to expression.”
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical firm that has traditionally worked to acquire novel therapies for neurodegenerative ailments. Synaptogenix has done clinical and preclinical experiments of its lead therapeutic applicant, Bryostatin-1, in Alzheimer’s ailment, and preclinical experiments for unusual conditions these types of as Fragile X syndrome, Niemann-Select Kind C disorder, and Rett syndrome, a number of sclerosis, stroke, and traumatic brain harm. The U.S. Foods and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment method for Fragile X syndrome. Bryostatin-1 has currently been through screening in far more than 1,500 folks in cancer reports, therefore producing a massive security facts base that will even further inform clinical trial patterns.
Additional information and facts about Synaptogenix, Inc. may be discovered on its internet site: www.synaptogen.com.
Any statements contained in this press release that do not describe historical specifics may constitute ahead-wanting statements. These ahead-seeking statements incorporate statements relating to the Company’s application for listing its prevalent shares on the Nasdaq Stock Market. This sort of forward-seeking statements are subject to hazards and uncertainties and other influences, many of which the Firm has no handle more than. There can be no assurance that the scientific application for Bryostatin-1 will be effective in demonstrating safety and/or efficacy, that we will not come upon issues or delays in medical development, or that Bryostatin-1 will ever get regulatory acceptance or be successfully commercialized. Precise results and the timing of selected situations and instances might vary materially from all those described by the forward-looking statements as a end result of these challenges and uncertainties. Further elements that may well influence or lead to actual benefits to vary materially from anticipated or desired benefits may perhaps include, without the need of limitation, the Firm’s inability to obtain ample funding, the sizeable duration of time related with drug progress and linked inadequate income flows and resulting illiquidity, the Company’s patent portfolio, the Company’s lack of ability to develop its small business, considerable governing administration regulation of pharmaceuticals and the healthcare market, absence of item diversification, availability of the Company’s raw products, present or increased levels of competition, inventory volatility and illiquidity, and the Company’s failure to put into action its business enterprise programs or procedures. These and other elements are identified and explained in additional element in the Firm’s filings with the Securities and Exchange Fee. The Corporation does not undertake to update these ahead-on the lookout statements.
Contact information and facts:
Investors and Media
Chief Economical Officer
Source Synaptogenix, Inc.